The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma

Experience on 74 patients

Pier Luigi Zinzani, Alessandro Broccoli, Beatrice Casadei, Vittorio Stefoni, Cinzia Pellegrini, Letizia Gandolfi, Roberto Maglie, Lisa Argnani, Stefano Pileri, Stefano Fanti

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Regarding primary mediastinal large B-cell lymphoma (PMLBCL), there are several controversial topics that warrant further investigation: the superiority of third-generation regimens, the impact of rituximab, the use of involved field radiotherapy (RT) and the assessment of clinical response by positron emission tomography (PET). We report our experience on 74 PMLBCL patients treated with a combination of a third-generation chemotherapy regimen (MACOP-B) and rituximab: an observational retrospective single-centre study was conducted on patients diagnosed and treated between February 2002 and July 2011. All patients were evaluated by computed tomography scan and PET scan; after the final PET evaluation, PET-negative patients were observed, whereas PET-positive patients underwent mediastinal RT. Sixty-one (82.4%) patients achieved a complete response after the MACOP-B plus rituximab regimen; 68.9% presented a positive final PET and were treated with local RT, whereas 31.1% had a negative PET. Five patients relapsed within 12months. At 10years, overall survival was 82%, progression-free survival was 87.6% and disease-free survival (DFS) was 90.5% (median follow-up 4years). No statistically significant differences were observed in DFS between the patients treated also with RT (PET positive) and patients only observed (PET negative): 90.7% vs 90% (p=0.85), respectively. In our experience, adding rituximab does not change the final results in terms of complete response and DFS utilizing third-generation regimen. Furthermore, the introduction of the PET-guided RT approach leads to a patient-tailored treatment, which preserves the outcome and, at the same time, allows reducing the use of RT.

Original languageEnglish
Pages (from-to)145-150
Number of pages6
JournalHematological Oncology
Volume33
Issue number4
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

B-Cell Lymphoma
Positron-Emission Tomography
Radiotherapy
Disease-Free Survival
Therapeutics
Rituximab
Drug Therapy
Survival

Keywords

  • MACOP-B regimen
  • PET scan
  • PMLBCL
  • Radiotherapy
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma : Experience on 74 patients. / Zinzani, Pier Luigi; Broccoli, Alessandro; Casadei, Beatrice; Stefoni, Vittorio; Pellegrini, Cinzia; Gandolfi, Letizia; Maglie, Roberto; Argnani, Lisa; Pileri, Stefano; Fanti, Stefano.

In: Hematological Oncology, Vol. 33, No. 4, 01.12.2015, p. 145-150.

Research output: Contribution to journalArticle

Zinzani, PL, Broccoli, A, Casadei, B, Stefoni, V, Pellegrini, C, Gandolfi, L, Maglie, R, Argnani, L, Pileri, S & Fanti, S 2015, 'The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: Experience on 74 patients', Hematological Oncology, vol. 33, no. 4, pp. 145-150. https://doi.org/10.1002/hon.2172
Zinzani, Pier Luigi ; Broccoli, Alessandro ; Casadei, Beatrice ; Stefoni, Vittorio ; Pellegrini, Cinzia ; Gandolfi, Letizia ; Maglie, Roberto ; Argnani, Lisa ; Pileri, Stefano ; Fanti, Stefano. / The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma : Experience on 74 patients. In: Hematological Oncology. 2015 ; Vol. 33, No. 4. pp. 145-150.
@article{278d206c7bfd46dfa66ce7488e5e8429,
title = "The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: Experience on 74 patients",
abstract = "Regarding primary mediastinal large B-cell lymphoma (PMLBCL), there are several controversial topics that warrant further investigation: the superiority of third-generation regimens, the impact of rituximab, the use of involved field radiotherapy (RT) and the assessment of clinical response by positron emission tomography (PET). We report our experience on 74 PMLBCL patients treated with a combination of a third-generation chemotherapy regimen (MACOP-B) and rituximab: an observational retrospective single-centre study was conducted on patients diagnosed and treated between February 2002 and July 2011. All patients were evaluated by computed tomography scan and PET scan; after the final PET evaluation, PET-negative patients were observed, whereas PET-positive patients underwent mediastinal RT. Sixty-one (82.4{\%}) patients achieved a complete response after the MACOP-B plus rituximab regimen; 68.9{\%} presented a positive final PET and were treated with local RT, whereas 31.1{\%} had a negative PET. Five patients relapsed within 12months. At 10years, overall survival was 82{\%}, progression-free survival was 87.6{\%} and disease-free survival (DFS) was 90.5{\%} (median follow-up 4years). No statistically significant differences were observed in DFS between the patients treated also with RT (PET positive) and patients only observed (PET negative): 90.7{\%} vs 90{\%} (p=0.85), respectively. In our experience, adding rituximab does not change the final results in terms of complete response and DFS utilizing third-generation regimen. Furthermore, the introduction of the PET-guided RT approach leads to a patient-tailored treatment, which preserves the outcome and, at the same time, allows reducing the use of RT.",
keywords = "MACOP-B regimen, PET scan, PMLBCL, Radiotherapy, Rituximab",
author = "Zinzani, {Pier Luigi} and Alessandro Broccoli and Beatrice Casadei and Vittorio Stefoni and Cinzia Pellegrini and Letizia Gandolfi and Roberto Maglie and Lisa Argnani and Stefano Pileri and Stefano Fanti",
year = "2015",
month = "12",
day = "1",
doi = "10.1002/hon.2172",
language = "English",
volume = "33",
pages = "145--150",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "4",

}

TY - JOUR

T1 - The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma

T2 - Experience on 74 patients

AU - Zinzani, Pier Luigi

AU - Broccoli, Alessandro

AU - Casadei, Beatrice

AU - Stefoni, Vittorio

AU - Pellegrini, Cinzia

AU - Gandolfi, Letizia

AU - Maglie, Roberto

AU - Argnani, Lisa

AU - Pileri, Stefano

AU - Fanti, Stefano

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Regarding primary mediastinal large B-cell lymphoma (PMLBCL), there are several controversial topics that warrant further investigation: the superiority of third-generation regimens, the impact of rituximab, the use of involved field radiotherapy (RT) and the assessment of clinical response by positron emission tomography (PET). We report our experience on 74 PMLBCL patients treated with a combination of a third-generation chemotherapy regimen (MACOP-B) and rituximab: an observational retrospective single-centre study was conducted on patients diagnosed and treated between February 2002 and July 2011. All patients were evaluated by computed tomography scan and PET scan; after the final PET evaluation, PET-negative patients were observed, whereas PET-positive patients underwent mediastinal RT. Sixty-one (82.4%) patients achieved a complete response after the MACOP-B plus rituximab regimen; 68.9% presented a positive final PET and were treated with local RT, whereas 31.1% had a negative PET. Five patients relapsed within 12months. At 10years, overall survival was 82%, progression-free survival was 87.6% and disease-free survival (DFS) was 90.5% (median follow-up 4years). No statistically significant differences were observed in DFS between the patients treated also with RT (PET positive) and patients only observed (PET negative): 90.7% vs 90% (p=0.85), respectively. In our experience, adding rituximab does not change the final results in terms of complete response and DFS utilizing third-generation regimen. Furthermore, the introduction of the PET-guided RT approach leads to a patient-tailored treatment, which preserves the outcome and, at the same time, allows reducing the use of RT.

AB - Regarding primary mediastinal large B-cell lymphoma (PMLBCL), there are several controversial topics that warrant further investigation: the superiority of third-generation regimens, the impact of rituximab, the use of involved field radiotherapy (RT) and the assessment of clinical response by positron emission tomography (PET). We report our experience on 74 PMLBCL patients treated with a combination of a third-generation chemotherapy regimen (MACOP-B) and rituximab: an observational retrospective single-centre study was conducted on patients diagnosed and treated between February 2002 and July 2011. All patients were evaluated by computed tomography scan and PET scan; after the final PET evaluation, PET-negative patients were observed, whereas PET-positive patients underwent mediastinal RT. Sixty-one (82.4%) patients achieved a complete response after the MACOP-B plus rituximab regimen; 68.9% presented a positive final PET and were treated with local RT, whereas 31.1% had a negative PET. Five patients relapsed within 12months. At 10years, overall survival was 82%, progression-free survival was 87.6% and disease-free survival (DFS) was 90.5% (median follow-up 4years). No statistically significant differences were observed in DFS between the patients treated also with RT (PET positive) and patients only observed (PET negative): 90.7% vs 90% (p=0.85), respectively. In our experience, adding rituximab does not change the final results in terms of complete response and DFS utilizing third-generation regimen. Furthermore, the introduction of the PET-guided RT approach leads to a patient-tailored treatment, which preserves the outcome and, at the same time, allows reducing the use of RT.

KW - MACOP-B regimen

KW - PET scan

KW - PMLBCL

KW - Radiotherapy

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84954538287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954538287&partnerID=8YFLogxK

U2 - 10.1002/hon.2172

DO - 10.1002/hon.2172

M3 - Article

VL - 33

SP - 145

EP - 150

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 4

ER -